Emergency & Toxicology

Benzodiazepine and sedative overdose

Clinical Overview and When to Suspect Benzodiazepine/Sedative Overdose

— Depressed mental status with preserved or only mildly depressed vital signs in an awake-appearing but somnolent patient

— Pill bottles at scene, known psychiatric/insomnia/seizure history, recent prescription refills

— Polysubstance ingestion (most overdose deaths involving benzos are co-ingestions with opioids or alcohol)

— Iatrogenic procedural sedation gone too deep

Key distinction: Benzo overdose → sedation with preserved respirations and normal pupils; opioid overdose → sedation with respiratory depression and miosis. This pupillary/respiratory pattern is the fastest bedside differentiator on the boards.

Definition: CNS depression from excessive ingestion of GABA-A agonists — benzodiazepines (alprazolam, clonazepam, diazepam, lorazepam, midazolam), Z-drugs (zolpidem, eszopiclone, zaleplon), barbiturates (phenobarbital, butalbital), or other sedative-hypnotics (chloral hydrate, meprobamate, GHB).

Mechanism: Benzodiazepines increase frequency of GABA-A chloride channel opening; barbiturates increase duration of opening (and at high doses directly open the channel — hence narrower therapeutic index and higher lethality alone).

When to suspect:

Pure benzodiazepine overdose is rarely fatal in isolation — deaths almost always involve co-ingestants. Barbiturate and GHB monointoxication, by contrast, can be lethal.

Toxidrome features: Sedation, slurred speech, ataxia, nystagmus, normal or near-normal pupils (distinguishes from opioids), hyporeflexia at high doses. Respiratory depression is typically mild unless co-ingestion, IV route, or barbiturate.

Epidemiology pearls: Elderly on chronic benzos at high risk for falls/delirium; adolescents and young adults for recreational/suicidal ingestion; chronic pain patients on combined opioid-benzo regimens are FDA black-box warned.

Presentation Patterns and Key History

History to obtain (collateral is critical):

— Exact agent, dose, time of ingestion, formulation (XR vs IR)

— Co-ingestants: alcohol, opioids, TCAs, antihistamines, antipsychotics

— Intent: suicidal vs accidental vs recreational vs therapeutic misuse

— Chronic use → tolerance and withdrawal risk if abruptly stopped

— Prescription review via state PDMP (prescription drug monitoring program)

— Prior overdoses, psychiatric history, access to firearms

Board pearl: Always ask about alcohol co-ingestion — synergistic respiratory depression converts a benign benzo ingestion into a life-threatening one. Ethanol level is mandatory in any sedative overdose.

Classic acute overdose: Progressive somnolence over 30–120 minutes after ingestion, slurred speech, unsteady gait, then obtundation. Patient is arousable to vigorous stimulation in pure benzo poisoning.

Ultra-short-acting agents (triazolam, midazolam, zolpidem): rapid onset, shorter coma duration (2–6 h).

Long-acting agents (diazepam, chlordiazepoxide, flurazepam): prolonged sedation 24–72 h due to active metabolites (desmethyldiazepam, oxazepam).

Barbiturate overdose: Deeper coma, hypotension, hypothermia, bullous skin lesions ("barb blisters") over pressure points, absent reflexes, may mimic brain death.

GHB: Rapid-onset coma with abrupt awakening at 2–4 hours; often combative on emergence.

Z-drug (zolpidem): Sedation plus characteristic complex sleep behaviors (sleep-driving, sleep-eating), anterograde amnesia.

Red flag history: Found unresponsive, snoring respirations, cyanosis, vomiting with airway concern, suspected aspiration, ingestion >30 mg alprazolam-equivalent, sustained-release formulation, or any pediatric exposure → high-acuity disposition.

Occupational/forensic clue: Date-rape scenario → consider GHB, flunitrazepam, ketamine; obtain urine toxicology and chain-of-custody specimens.

Physical Exam Findings and Hemodynamic Assessment

— Respiratory rate: Normal or mildly decreased in pure benzo OD; markedly depressed with opioid/alcohol co-ingestion or barbiturates

— Heart rate: Usually normal; bradycardia suggests barbiturate, beta-blocker, or opioid co-ingestion

— Blood pressure: Normotensive in benzo OD; hypotension suggests barbiturate, propofol, or volume depletion

— Temperature: Hypothermia common in barbiturate/prolonged exposure; hyperthermia suggests serotonergic or sympathomimetic co-ingestion

— SpO2: May lag behind hypoventilation — use end-tidal CO2 for early detection

— GCS variably depressed; arousable to sternal rub in pure benzo

— Pupils: Normal size, reactive (key differentiator)

— Horizontal/vertical nystagmus, dysarthria, ataxia, hyporeflexia

— Absent brainstem reflexes in deep barbiturate coma — do not declare brain death without toxicology clearance

Step 3 management: First 60 seconds at bedside — ABCs first. Open airway with jaw thrust, apply oxygen, attach continuous SpO2 and capnography, place on monitor, establish IV access, obtain fingerstick glucose. Don't reach for flumazenil reflexively.

— Hypotensive + bradycardic + hypothermic + bullae → barbiturate

— Hypotensive + bradycardic + miotic + apneic → opioid co-ingestion

— Normotensive + sedated + normal pupils → isolated benzo/Z-drug

— Sedated + tachycardic + mydriatic + dry → anticholinergic co-ingestion (TCA, diphenhydramine)

Vital signs:

Neurologic:

Airway assessment: Pooled secretions, gag reflex, snoring respirations → aspiration risk

Skin: Track marks (IV abuse), bullae over pressure points (barbiturate, "coma blisters"), needle sticks

Cardiopulmonary: Auscultate for aspiration crackles; assess capillary refill and JVP

Hemodynamic patterns to recognize:

Repeat exams q15–30 min in the ED; sedative levels can rise with delayed absorption from XR formulations or pylorospasm.

Diagnostic Workup — Initial Labs, Imaging, ECG, Biomarkers

— Fingerstick glucose (hypoglycemia mimics sedation)

— Continuous pulse oximetry and capnography

— 12-lead ECG

— CBC, BMP (electrolytes, BUN/Cr, anion gap)

— Liver function tests (chronic benzo users often have hepatic dysfunction)

— Venous or arterial blood gas — respiratory acidosis indicates hypoventilation

— Lactate (elevated suggests hypoperfusion or co-ingestion)

— Creatine kinase (rhabdomyolysis from prolonged immobility)

— Serum acetaminophen and salicylate levels — mandatory in every intentional overdose

— Serum ethanol level

— Pregnancy test (β-hCG) in any female of reproductive age

— Wide QRS (>100 ms) → suspect TCA or other sodium-channel blocker co-ingestion

— Prolonged QTc → methadone, antipsychotic, citalopram co-ingestion

— Bradyarrhythmia → beta-blocker, CCB, digoxin co-ingestion

— CXR if aspiration suspected, hypoxia, or prolonged down-time

— Non-contrast head CT if focal neuro deficit, trauma, or sedation out of proportion to ingestion history

Board pearl: A negative urine benzodiazepine immunoassay does not rule out benzo overdose — alprazolam, clonazepam, and lorazepam are metabolized to compounds the assay misses. Trust the clinical picture, not the cup.

Bedside immediately:

Core labs:

Urine drug screen: Limited utility — qualitative only, many false negatives (alprazolam, clonazepam, lorazepam often miss the immunoassay; most Z-drugs are not detected); does not change acute management.

ECG findings to chase:

Imaging:

Why acetaminophen/salicylate are mandatory: Co-ingestion is common in suicide attempts, and missing APAP toxicity within the treatment window for N-acetylcysteine is a classic Step 3 trap.

Cooximetry if carbon monoxide suspected (housefire, garage suicide attempt with sedative).

Diagnostic Workup — Advanced or Confirmatory Studies

— Phenobarbital level is the exception — guides decisions about urinary alkalinization and hemodialysis (levels >100 mcg/mL or severe instability → HD)

— Benzodiazepine quantitative levels not clinically useful

— Focal neurologic findings

— Signs of trauma (especially in elderly fallers on chronic benzos)

— Persistent altered mental status beyond expected duration

— Mental status deteriorates after initial improvement

— Suspicion of nonconvulsive status epilepticus masquerading as persistent obtundation

— Subtle motor activity (eye fluttering, jaw movements)

— Failure to awaken as expected

Key distinction: Persistent unresponsiveness despite expected drug clearance demands a rethink — non-convulsive status, anoxic injury, intracranial hemorrhage (especially elderly fall), undiagnosed co-ingestion, or hepatic/uremic encephalopathy.

— Massive ingestions, sustained-release formulations

— Pediatric exposures (any benzo in a child <6 → ED evaluation)

— Consideration of flumazenil

— Suspected unusual agents (GHB, kratom-benzo combos, novel "designer" benzos like etizolam, clonazolam — often miss standard immunoassays)

Quantitative drug levels rarely guide acute care:

Confirmatory testing via GC-MS or LC-MS reserved for forensic, occupational, or unclear presentations — turnaround too slow for acute decisions.

CT head: Indicated when:

EEG: Consider if:

Lumbar puncture: If fever, meningismus, or unexplained encephalopathy after toxicologic workup negative.

Echocardiography: If cardiogenic shock suspected from co-ingestant (TCA, CCB, beta-blocker).

Aspiration evaluation: Repeat CXR at 4–6 h if initial clear but high clinical suspicion; consider bronchoscopy for large-particle aspiration.

Toxicology consult / Poison Control (1-800-222-1222): Call for:

Psychiatric evaluation: Once medically clear, mandatory for all intentional overdoses before disposition.

Risk Stratification and First-Line Management Logic

— Mild: Drowsy, arousable, protecting airway, normal vitals → observation

— Moderate: Markedly sedated, ataxic, slurred, mild hypoventilation → monitored bed, supportive care

— Severe: Unresponsive, hypoventilation, hypotension, aspiration → ICU, airway intervention

1. Airway/breathing: Position, suction, supplemental O2; intubate for GCS ≤8, loss of gag, hypoventilation with rising EtCO2, or aspiration

2. Circulation: IV crystalloid for hypotension; vasopressors if refractory (norepinephrine first-line)

3. Decontamination: Activated charcoal 1 g/kg within 1 hour of ingestion only if airway is protected (intubated or fully awake) — generally not recommended routinely as benzos are well absorbed and most patients present late. Never gastric lavage for benzos.

4. Empiric antidotes only if indicated: Naloxone if opioid co-ingestion suspected; dextrose if hypoglycemic; thiamine before glucose in malnourished; flumazenil only in highly selected cases (see chunk 7)

5. Treat co-ingestants: Sodium bicarbonate for TCA-induced wide QRS, NAC for APAP, etc.

— Awake, baseline mental status, normal vitals × 4–6 h observation → medical clearance, then psych eval

— Persistent sedation, abnormal vitals, intubated → ICU

— Suicidal intent → 1:1 sitter, ligature precautions, involuntary hold per state law

Step 3 management: The cornerstone of pure benzo overdose care is supportive — airway protection and observation. Most deaths are preventable with good airway management; antidotal therapy is rarely needed and often harmful.

Severity tiers:

Management framework — "Support, don't antagonize":

Disposition logic:

CCS pearl: Order in this sequence — "Pulse ox + capnography, IV access, fingerstick glucose, naloxone if RR <12, labs including APAP/salicylate/ethanol, ECG, monitored bed, q1h neuro checks, psych consult when stable."

Pharmacotherapy — Flumazenil and Adjuncts

— Dose: 0.2 mg IV over 30 sec, repeat 0.3 mg, then 0.5 mg q1 min up to 3–5 mg total

— Onset: 1–2 min; duration: 30–60 min (often shorter than the benzodiazepine → resedation likely)

— Indications (narrow):

1. Iatrogenic procedural sedation oversedation in a benzo-naïve patient

2. Pediatric accidental single-agent benzo ingestion (selected)

3. Diagnostic in unclear coma when benzo is the only plausible cause and no contraindications

— Contraindications (broad — these are testable):

1. Chronic benzodiazepine use → precipitates withdrawal seizures

2. Known seizure disorder treated with benzos

3. Suspected TCA or other proconvulsant co-ingestion (wide QRS, anticholinergic signs) → unopposed seizure activity, refractory

4. Increased ICP, status epilepticus

5. Hemodynamic instability

Board pearl: A patient on chronic alprazolam who took an extra handful with wine → do NOT give flumazenil. The right answer is intubate if needed, monitor, observe. Flumazenil here can cause status epilepticus.

— Naloxone 0.04–0.4 mg IV titrated for suspected opioid co-ingestion

— Dextrose D50 25 g IV if hypoglycemic

— Thiamine 100 mg IV before glucose in suspected alcohol use disorder

— Sodium bicarbonate 1–2 mEq/kg bolus for TCA-induced QRS widening

— IV crystalloid for hypotension; norepinephrine if refractory

Flumazenil — competitive GABA-A benzodiazepine receptor antagonist:

Why boards hate flumazenil: Risk of seizure, arrhythmia, and resedation outweighs benefit in nearly all adult overdose cases. Default answer: supportive care, not flumazenil.

Adjunctive pharmacotherapy:

Barbiturate-specific: Urinary alkalinization with sodium bicarb (urine pH >7.5) for phenobarbital enhances elimination. Multi-dose activated charcoal also reduces phenobarbital half-life. Hemodialysis for severe phenobarbital toxicity (levels >100, refractory hypotension, prolonged coma).

GHB: No antidote; supportive care; resolves spontaneously in 2–6 h.

Expanded Management — Airway, ICU, and Extracorporeal Therapies

— GCS ≤8 with loss of airway protection

— Rising EtCO2 (>50–55 mmHg) or PaCO2 with acidemia

— SpO2 <90% on supplemental O2

— Active vomiting with depressed gag

— Need for procedures (CT, transport) in unstable patient

— RSI agents: etomidate or ketamine preferred (avoid additional sedatives if possible); succinylcholine or rocuronium for paralysis

— Lung-protective settings (Vt 6–8 mL/kg IBW)

— Treat aspiration pneumonitis supportively; no empiric antibiotics unless infection develops at 48–72 h

— Sedation post-intubation: propofol preferred (short half-life allows neuro reassessment) — avoid additional benzodiazepines

— IV crystalloid bolus 20–30 mL/kg for hypotension

— Norepinephrine first-line vasopressor; add vasopressin if refractory

— Consider co-ingestant-specific therapy: glucagon/high-dose insulin for beta-blocker/CCB, lipid emulsion for severe TCA or local anesthetic toxicity

— Benzodiazepines: Not dialyzable (high protein binding, large Vd)

— Phenobarbital: Hemodialysis effective; consider for levels >100 mcg/mL, refractory hypotension, or prolonged coma

— Meprobamate, chloral hydrate: Hemodialysis can be considered for severe cases

— Z-drugs, GHB: Not dialyzable, supportive care only

— Activated charcoal only if <1 h post-ingestion AND airway protected

— Whole-bowel irrigation reserved for massive sustained-release ingestion or body packers — rarely indicated for sedatives

CCS pearl: Once intubated for benzo overdose, the management clock is — extubate when patient follows commands, has adequate cough, RSBI <105, and minimal sedation requirements. Daily spontaneous awakening trials prevent prolonged ICU stays.

Airway management — when to intubate:

Mechanical ventilation considerations:

Hemodynamic support:

Extracorporeal removal:

Decontamination revisited:

Prolonged ICU course red flags: Rhabdomyolysis (CK >5000), aspiration pneumonia at 48–72 h, anoxic brain injury from pre-hospital hypoxia, DVT prophylaxis with enoxaparin.

Special Populations — Elderly and Renal/Hepatic Impairment

— Beers Criteria lists benzodiazepines and Z-drugs as potentially inappropriate in adults ≥65 due to fall, fracture, delirium, and MVA risk

— Reduced hepatic clearance and increased volume of distribution → prolonged half-lives (diazepam half-life can reach 100+ hours in elderly)

— Increased sensitivity to GABA-A modulation independent of pharmacokinetics

— Even therapeutic doses can cause significant impairment

— Paradoxical reactions more common (agitation, disinhibition)

— Lower threshold for ICU admission and prolonged observation

— Aggressive fall and aspiration precautions

— Workup for fall-related injuries (hip fracture, subdural hematoma) — low threshold for head CT and pelvic imaging

— Avoid flumazenil even more strictly — high rates of chronic use

— Delirium prevention bundle: reorientation, mobility, sleep hygiene, avoid further sedatives

— Most benzos undergo hepatic oxidation (CYP3A4) → prolonged in cirrhosis

— Preferred agents in liver disease (LOT): Lorazepam, Oxazepam, Temazepam — undergo glucuronidation only, no active metabolites

— Diazepam, chlordiazepoxide, alprazolam → avoid in advanced liver disease

— Overdose in cirrhotic patient → expect prolonged coma; monitor for hepatic encephalopathy as differential

— Less impact on benzo metabolism (mostly hepatic)

— Phenobarbital partially renally cleared — adjust and monitor

— Z-drugs require dose reduction in severe renal disease

Board pearl: "LOT is hepatically safe" — Lorazepam, Oxazepam, Temazepam are the benzos that bypass CYP oxidation and are preferred in liver disease, elderly, and alcohol withdrawal in cirrhotics.

Elderly patients:

Management adjustments:

Hepatic impairment:

Renal impairment:

Discharge planning for elderly: Coordinate deprescribing — taper benzos slowly (10–25% per 2 weeks), engage primary care, consider CBT-I for insomnia.

Special Populations — Pregnancy, Pediatrics, Substance Use Disorder

— Benzos cross placenta freely; Category D (older designation) for most

— Acute maternal overdose: prioritize maternal resuscitation — left lateral tilt after 20 weeks, fetal monitoring once mother stabilized

— Flumazenil safety in pregnancy unestablished; still contraindicated if chronic use

— Neonatal effects from chronic third-trimester use: "floppy infant syndrome" (hypotonia, hypothermia, poor feeding, respiratory depression) and neonatal abstinence syndrome (irritability, tremors, seizures)

— First-trimester exposure: small associations with cleft lip/palate (data mixed); do not abruptly discontinue therapeutic benzos in pregnancy — withdrawal risk to mother and fetus

— "One pill can kill" does not apply to most benzos (relatively safe) but does apply to chloral hydrate, methadone, and some sustained-release barbiturates

— Any pediatric benzo ingestion → ED evaluation and 6-h observation minimum

— Z-drug ingestion in children: rare but reported sleep behaviors and prolonged sedation

— Flumazenil can be considered in pediatric pure benzo ingestions (no chronic exposure) — pediatric tox consult recommended

— Always consider non-accidental ingestion / child abuse in toddlers with sedative overdose → social work, CPS report

— Chronic high-dose benzo use → severe withdrawal risk (seizures, delirium tremens-like syndrome) if abruptly stopped post-overdose

— Plan structured taper during admission; do not discharge on same regimen after suicide attempt without psych input

— Co-prescribed opioid + benzo: FDA black-box, naloxone prescription mandatory at discharge, consider buprenorphine-favored regimens

— Screen for alcohol use disorder — CIWA monitoring if heavy drinker

Step 3 management: A pregnant patient with chronic benzo use who overdoses → stabilize mother, fetal monitoring per gestational age, do not abruptly stop benzos post-admission; engage MFM and psychiatry for structured taper plan.

Pregnancy:

Pediatrics:

Substance use disorder patients:

Reporting obligations: Suspected child abuse, intimate partner violence (drug-facilitated assault with flunitrazepam/GHB), or elder neglect mandate notification per state law.

Complications and Adverse Outcomes

— Aspiration pneumonitis (acute chemical injury, within hours) → progresses to pneumonia in ~25% at 48–72 h

— Hypoventilation → hypercapnic respiratory failure

— Atelectasis, ARDS in severe/prolonged cases

— Negative-pressure pulmonary edema post-intubation

— Hypotension (volume depletion, vasodilation, co-ingestants)

— Arrhythmias usually reflect co-ingestion (TCA, methadone, antipsychotics)

— Cardiac arrest in severe barbiturate or polysubstance overdose

— Anoxic brain injury from prolonged hypoxia pre-hospital — leading cause of permanent disability

— Compartment syndrome from prolonged immobility on dependent limb

— Peripheral nerve palsies (radial, peroneal) from pressure

— Withdrawal seizures if flumazenil given inappropriately or abrupt cessation in chronic user

— Rhabdomyolysis from prolonged immobility — check CK, urine myoglobin, IV fluids to maintain UOP >1 mL/kg/h

— AKI from rhabdo, hypotension, or co-ingestant

— Pressure ulcers from prolonged down-time

— Aspiration during intubation

— Flumazenil-induced seizures, arrhythmias

— Over-sedation from added benzos in ICU (avoid!)

— Line/airway complications

— Repeat self-harm — highest risk in first week post-discharge from suicide attempt

— Persistent depression, PTSD from ICU stay

Key distinction: Pure benzo overdose mortality is very low (<1%); polysubstance overdose mortality is high (5–10%+) depending on co-ingestants. The clinical question isn't usually "Will the benzo kill them?" but rather "What else did they take?"

Respiratory:

Cardiovascular:

Neurologic:

Musculoskeletal/renal:

Iatrogenic:

Psychiatric:

Long-term: Chronic benzo use → cognitive impairment, increased dementia risk (associations debated), dependence, withdrawal syndromes, MVA risk.

When to Escalate Care — ICU, Consult, Inpatient Triage

— Intubated patients

— GCS ≤8 not yet intubated but trending down

— Hemodynamic instability requiring vasopressors

— Severe acid-base or electrolyte derangement

— Co-ingestion requiring specific monitoring (TCA with wide QRS, massive APAP, lithium)

— Phenobarbital toxicity requiring HD or alkalinization

— Recurrent seizures

— Aspiration with respiratory failure

— Persistent sedation but stable airway and vitals

— Co-ingestion with anticipated decompensation

— Elderly with normal vitals but slow clearance expected

— Cleared medically but awaiting psychiatric placement

— Mild persistent symptoms needing observation

— Awake, alert, normal vitals × 4–6 h observation

— No co-ingestants requiring monitoring

— Reliable observer for next 24 h (if accidental)

— Psychiatric clearance for intentional ingestions

— Naloxone Rx if co-prescribed opioids

— Medical toxicology / Poison Control — for severe, atypical, or pediatric cases; flumazenil consideration

— Psychiatry — mandatory for all intentional overdoses before medical discharge

— Social work — for placement, addiction services, IPV/abuse concerns

— Addiction medicine — for SUD patients, consider MAT

— Pharmacy — review home med list, identify high-risk combinations, deprescribing

— Primary care follow-up within 7 days post-discharge for medication reconciliation and taper supervision

CCS pearl: For an intubated benzo overdose patient: ICU admission, propofol drip (NOT benzos), DVT prophylaxis with enoxaparin, stress ulcer prophylaxis with PPI, head of bed 30°, daily spontaneous awakening + breathing trials, psychiatry consult for post-extubation evaluation.

ICU admission criteria:

Step-down/telemetry monitored bed:

Floor admission:

Discharge from ED:

Consultations:

Transfer criteria: Lack of ICU bed, pediatric specialty needs, ECMO consideration in catastrophic polysubstance → transfer to tertiary center after stabilization.

Key Differentials — Other Sedative/Toxic Causes

— Opioid overdose: Triad of miosis + respiratory depression + sedation; responds to naloxone — key differentiator is pinpoint pupils and prominent respiratory depression

— Barbiturate overdose: Deeper coma, hypotension, hypothermia, bullous skin lesions, absent reflexes; can mimic brain death

— GHB/GBL: Rapid-onset coma with abrupt awakening in 2–6 h; often combative on emergence; date-rape context

— Z-drug overdose: Similar to benzos but shorter duration; complex sleep behaviors distinctive

— Alcohol intoxication: Smell, ataxia, slurred speech, elevated ethanol; check osmolar gap (additional toxic alcohols)

— Antipsychotic overdose: Sedation + anticholinergic + EPS + QT prolongation; consider quetiapine, olanzapine

— Antihistamine (diphenhydramine) overdose: Anticholinergic toxidrome (hot, dry, mydriatic, tachycardic, delirious) — distinct from sedative toxidrome despite sedation

— Clonidine/tizanidine: Sedation, miosis (mimics opioid!), bradycardia, hypotension; partial naloxone response sometimes seen

— Gabapentin/pregabalin: Increasingly common; sedation, myoclonus; renally cleared

— Etizolam, flubromazolam, clonazolam — "designer benzos" available online; negative on routine immunoassays; clinical presentation identical

— Kratom: sedation + opioid-like effects

Key distinction: Sedated patient with miosis — three big options:

1. Opioids (respiratory depression prominent)

2. Clonidine (bradycardia, hypotension)

3. Organophosphate (SLUDGE/DUMBBELS, fasciculations)

Benzodiazepines do not cause miosis — pupils are normal.

Within sedative-hypnotic class:

Designer/novel agents:

Diagnostic approach: Toxidrome recognition > urine drug screen. Match the vital sign pattern, pupil exam, skin findings, and reflexes to narrow the differential before chasing labs.

Key Differentials — Non-Toxicologic Causes of Altered Mental Status

— Alcohol (intoxication, withdrawal, Wernicke)

— Endocrine (hypoglycemia, DKA, HHS, myxedema, adrenal crisis, hyperthyroid storm)

— Infection (sepsis, meningitis, encephalitis, UTI in elderly)

— Oxygen (hypoxia, CO poisoning) / Opiates

— Uremia, hepatic encephalopathy

— Trauma (especially subdural hematoma in elderly fallers on benzos)

— Insulin / hypoglycemia

— Psychiatric (catatonia, conversion)

— Stroke, Seizure (postictal, non-convulsive status), Shock

— Hypoglycemia in diabetic on sulfonylurea — always check fingerstick first

— Non-convulsive status epilepticus — persistent obtundation after expected drug clearance; EEG diagnostic

— Wernicke encephalopathy — chronic alcohol use, ataxia + ophthalmoplegia + confusion; treat empirically with thiamine before glucose

— Hepatic encephalopathy — asterixis, hyperammonemia in cirrhotic; benzos worsen it (and benzo overdose may be the trigger)

— CO poisoning — house fire, garage, headache, cherry-red is unreliable; check carboxyhemoglobin

— Stroke — focal deficits, asymmetry on exam; obtain CT/MRI

— CNS infection — fever, meningismus, immunocompromise

Step 3 management: When mental status doesn't improve as expected from a presumed sedative overdose, broaden the differential — repeat fingerstick, expand labs (ammonia, TSH, cortisol, lactate), obtain CT head, consider LP and EEG. Anchoring to the toxicology story is a known cognitive error.

AEIOU-TIPS mnemonic drives the broader workup when toxicology doesn't fit:

High-yield mimics in the Step 3 stem:

Postoperative sedation: Residual anesthetic, opioid PCA, hypercarbia, hypoxia, stroke, electrolyte abnormality — don't blame benzos reflexively in a recovering surgical patient.

Elderly fall trap: Chronic benzo user found down → don't miss the subdural hematoma. Head CT is essentially mandatory in this population.

Secondary Prevention, Discharge Planning, and Long-Term Care

— Medical clearance: stable vitals, baseline mental status, tolerating PO, no acute complications

— Psychiatric evaluation completed for intentional ingestions

— Medication reconciliation — identify and address high-risk combinations

— Lethal means restriction — pill counts dispensed, blister packs, lockboxes, family-controlled storage

— Naloxone prescription if co-prescribed opioids (FDA recommendation)

— Suicide safety plan documented

— Outpatient follow-up scheduled within 7 days

— Indication: long-term use without clear benefit, falls, cognitive impairment, post-overdose

— Taper slowly: Reduce dose by 5–25% every 2–4 weeks; slower as dose lowers

— Convert short-acting (alprazolam) to long-acting (diazepam, clonazepam) for smoother taper if needed

— Anticipate withdrawal: anxiety, insomnia, tremor, autonomic instability, seizures

— Use adjuncts: SSRIs/SNRIs for underlying anxiety, gabapentin (controversial), CBT

— First-line: CBT-I (cognitive behavioral therapy for insomnia)

— Sleep hygiene education

— If pharmacotherapy needed: melatonin, low-dose doxepin, ramelteon, suvorexant

— First-line: SSRI/SNRI + psychotherapy; benzodiazepines are not first-line maintenance therapy

— Short-term benzo use only as bridge while SSRI titrates (≤2–4 weeks)

— FDA black box; both meds carry naloxone Rx mandate

— Whenever possible, taper one or both; CDC opioid guidelines support avoidance

Board pearl: Post-overdose, continuing the exact same benzo regimen that the patient overdosed on is a wrong answer. Address the underlying disorder (depression, anxiety, insomnia) with evidence-based long-term therapy, taper the benzo.

Pre-discharge checklist:

Deprescribing chronic benzodiazepines:

Insomnia management without sedative-hypnotics:

Anxiety disorders:

Opioid-benzo co-prescription:

Health-systems lens: Engage PCP, behavioral health, pharmacist; use PDMP at every refill; consider value-based care metrics for high-risk prescribing.

Follow-Up, Monitoring Parameters, and Counseling

— Within 7 days post-discharge: Primary care or behavioral health visit (highest re-attempt risk window after suicide attempt)

— 2 weeks: Psychiatry follow-up for medication initiation/adjustment

— Monthly during taper: PCP visits to monitor withdrawal, mood, function

— Quarterly after stabilization: Routine care; reassess need for any remaining sedatives

— Withdrawal symptoms (CIWA-B or clinical assessment): anxiety, tremor, insomnia, perceptual disturbances, autonomic signs

— Suicidality screening (PHQ-9, C-SSRS) at every visit

— Substance use (urine drug screen if SUD)

— Cognitive function in elderly

— Fall risk reassessment in elderly

— Avoid alcohol absolutely while on any benzo

— Avoid driving when starting/adjusting benzos

— Recognize and report withdrawal symptoms during taper

— Lethal means counseling: secure all medications, firearms, sharps

— Crisis resources: 988 Suicide & Crisis Lifeline, local emergency contacts

— Naloxone training for household if opioids co-prescribed

— Outpatient SUD treatment if indicated

— CBT or DBT for underlying psychiatric disorder

— Peer support groups (Benzodiazepine Information Coalition, SMART Recovery)

— Pulmonary rehab if aspiration pneumonia caused functional decline

— PT/OT if deconditioning from prolonged ICU stay

Step 3 management: The single most important follow-up intervention after intentional overdose is a face-to-face contact within 1 week of discharge — evidence shows this reduces repeat attempts substantially. Phone follow-up alone is insufficient.

Outpatient follow-up cadence:

Monitoring parameters:

Counseling points for patient and family:

Rehab and adjunctive services:

Documentation: Clearly document discharge mental status, capacity assessment, safety planning, lethal means counseling — protects against medicolegal liability and supports continuity.

Ethical, Legal, and Patient Safety Considerations

— Acutely intoxicated patients lack capacity to refuse care during the overdose itself

— Implied consent doctrine permits emergency treatment when patient cannot consent and refusal would result in serious harm

— Once sober, capacity must be reassessed before any AMA discharge — and after intentional overdose, involuntary psychiatric hold is appropriate when suicidal risk persists

— Danger to self, danger to others, or grave disability secondary to mental illness

— Document specific behaviors and statements, not conclusions

— Time-limited (typically 72 h emergency hold); judicial review required for extension

— Child abuse/neglect — suspected non-accidental pediatric ingestion

— Elder abuse — medication mismanagement in dependent adult

— Intimate partner violence — drug-facilitated assault (GHB, flunitrazepam)

— Impaired drivers — varies by state; California, Pennsylvania, others mandate physician reporting

— Discharging patient on same benzo regimen they overdosed on without addressing underlying disorder

— Failure to communicate medication changes to PCP at discharge

— Not flagging PDMP for high-risk prescribing combinations

— Missing co-prescribed opioids in medication reconciliation

— Sending patient home with weeks of supply rather than blister packs or small dispense

— Review PDMP before every benzo prescription

— Avoid co-prescription of benzos and opioids (FDA black-box)

— Document indication, plan for review, and exit strategy

— Use lowest effective dose for shortest duration

Board pearl: A patient who survives an intentional overdose and now refuses psychiatric evaluation, claiming they're "fine" — this is not capacity to refuse. Place an involuntary hold and ensure psychiatric assessment before discharge. Respecting autonomy does not mean enabling lethal harm.

Capacity and informed consent:

Involuntary hold criteria (vary by state):

Mandatory reporting:

Transition-of-care safety risks (Step 3 favorite):

Prescriber responsibilities:

Confidentiality vs duty to warn: Tarasoff-type duty applies if patient threatens identifiable third party.

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: When the stem describes "sedated patient with normal vitals and normal pupils, awakening to vigorous stimulation, history of anxiety disorder" — that's a pure benzodiazepine overdose, and the answer is supportive care, not flumazenil.

Pupils: Benzo OD = normal pupils; opioid = miosis; anticholinergic = mydriasis. Always check pupils first.

Most lethal sedative class: Barbiturates (narrow therapeutic index, direct channel opening at high doses)

Polysubstance combination most likely to kill: Benzodiazepine + opioid (or + alcohol) — FDA black-box warning

Hepatically "safe" benzos: LOT — Lorazepam, Oxazepam, Temazepam (glucuronidation only)

Longest-acting benzo: Diazepam (and its active metabolite desmethyldiazepam, t½ up to 200 h in elderly)

Shortest-acting clinically used benzo: Midazolam (t½ 1–4 h)

Z-drug specifically associated with complex sleep behaviors: Zolpidem

GHB clinical signature: Rapid coma → abrupt awakening at 2–6 h, often combative

"Barb blisters": Bullous skin lesions over pressure points in barbiturate overdose

Drug NOT detected on routine urine benzo immunoassay: Alprazolam, clonazepam, lorazepam (frequently miss); all Z-drugs; "designer benzos" (etizolam, clonazolam)

Antidote: Flumazenil — but rarely indicated; contraindicated in chronic users, TCA co-ingestion, seizure disorder

Phenobarbital toxicity enhanced elimination: Urinary alkalinization + multi-dose activated charcoal; hemodialysis for severe cases

GHB antidote: None — supportive care

Pregnancy concerns: Floppy infant syndrome, neonatal abstinence, possible cleft palate

Beers Criteria: Avoid benzos and Z-drugs in adults ≥65

FDA black-box pairings: Opioids + benzos; co-prescribe naloxone if unavoidable

First-line insomnia therapy: CBT-I, not sedative-hypnotics

Top cause of preventable death in benzo OD: Pre-hospital hypoxia/aspiration → anoxic brain injury

Highest re-attempt risk: First week after discharge from a suicide attempt

Always order in intentional OD: APAP level, salicylate level, ethanol, β-hCG, ECG

Board Question Stem Patterns

— Answer: Supportive care, airway monitoring, observation. NOT flumazenil (risk of withdrawal seizures in chronic user).

— Answer: Opioid, not benzo. Benzo OD has normal pupils and preserved respirations.

— Answer: Suspect TCA co-ingestion; give sodium bicarbonate, NOT flumazenil (would worsen seizure risk).

— Answer: Head CT to rule out subdural hematoma. Don't anchor on benzo intoxication.

— Answer: Negative immunoassay does NOT rule out benzo OD (alprazolam, clonazepam, lorazepam often missed). Treat clinically.

— Answer: Phenobarbital toxicity. Consider urinary alkalinization ± hemodialysis.

— Answer: Involuntary psychiatric hold; capacity is impaired by ongoing suicidal ideation; obtain psych eval.

— Answer: Continue lorazepam (don't precipitate withdrawal), MFM and psychiatry consult, structured taper if appropriate, counsel re: neonatal withdrawal.

— Lesson tested: Failure of safe discharge planning; correct answer involves deprescribing, lethal means restriction, close follow-up.

Step 3 management: Recognize these patterns reflexively — the test rewards recognition over recall. Most stems hinge on "supportive care vs antidote," "benzo vs opioid pupils," and "what did they ALSO take?"

Stem 1 — The flumazenil trap: Chronic alprazolam user found obtunded after extra dose with wine. Vitals stable. Pupils normal. What's the next best step?

Stem 2 — The pupil differentiator: Patient found unresponsive with RR 6, pinpoint pupils, BP 90/60. Naloxone given → improvement. Identify the toxidrome.

Stem 3 — The co-ingestion catch: Overdose patient with wide QRS on ECG and sedation.

Stem 4 — The elderly faller: Chronic clonazepam user, age 78, found at bottom of stairs, confused. Next step?

Stem 5 — The "negative urine": Suicidal patient, sedated, urine benzo screen negative. Now what?

Stem 6 — The barbiturate clue: Coma, hypotension, hypothermia, bullae on pressure points.

Stem 7 — The disposition decision: Awake intentional benzo OD patient now demanding to leave AMA.

Stem 8 — The pregnancy stem: Pregnant woman with chronic benzo use on lorazepam presents after small overdose. Now stable. Management plan?

Stem 9 — The medication reconciliation: Patient discharged after benzo OD with same prescription unchanged → 2 weeks later returns with repeat overdose.

Stem 10 — Z-drug oddity: Patient ate dinner and drove car last night with no memory. On zolpidem. Diagnosis: Complex sleep behavior; stop zolpidem.

One-Line Recap

Benzodiazepine and sedative-hypnotic overdose is a clinical diagnosis defined by sedation with preserved respirations and normal pupils, managed with airway-focused supportive care rather than reflexive antidote use, while the real mortality risk lies in co-ingestants — opioids, alcohol, TCAs — and the real preventable harm lies in unsafe discharge.

Toxidrome triad: Sedation + normal pupils + preserved respirations (until co-ingestant or barbiturate proves otherwise) — pupils and respiratory rate are your fastest bedside differentiators from opioid overdose.

Flumazenil is the wrong answer 95% of the time on Step 3: Contraindicated in chronic users (withdrawal seizures), suspected TCA co-ingestion (unopposed proconvulsant effect), seizure disorder, and hemodynamic instability; the right answer is airway protection, oxygen, monitoring, and treating co-ingestants.

Always order APAP level, salicylate level, ethanol, β-hCG, ECG, and check fingerstick glucose on every intentional overdose — the missed acetaminophen co-ingestion within the NAC window is the classic catastrophic Step 3 error.

Safe discharge is as important as resuscitation: Psychiatric clearance, lethal means restriction, naloxone Rx if opioids on board, deprescribing plan rather than refilling the same regimen, and a face-to-face follow-up within 7 days — because the highest risk of repeat attempt is the first week post-discharge, and the boards (and real practice) test transitions of care as rigorously as the initial resuscitation.